their food and the PDVs are released in the alkaline environment of the insect midgut (Fig. 1) . The liberated PDVs infect midgut columnar epithelial cells and the infected cells produce the BV type, which is required for secondary infection and systemic spread within insects. This type also infects cells in culture. Cellular entry of BV occurs through adsorptive endocytosis [7] . Following penetration of the plasma membrane, the nucleocapsids move towards the nucleus, the viral DNA is released, and the virus undergoes repeated rounds of transcription and replication. By 12 hours postinfection, the progeny BVs are formed and are released into the extracellular milieu and, soon thereafter, mature PDVs are occluded into OBs. The polyhedrin protein is dispensable for infection in cultured cells. Most baculovirus expression vector systems exploit this phenomenon by replacing the polyhedrin coding region with a foreign gene [1] . However, in nonpermissive insect cells, the host range of AcMNPV is limited not by its inability to enter and uncoat but rather by its ability to replicate and transcribe its genes. A major breakthrough came in 1983 when Volkman and Goldsmith [8] demonstrated that baculoviruses were able to enter certain cell lines derived from vertebrate species and that no evidence of viral gene expression was observed. This revolutionized the manipulation of AcMNPV with regard to its ability to infect mammalian cells [9][10][11]. Several recent publications have demonstrated gene transfer and expression in mammalian cells mediated by recombinant AcMNPV carrying mammalian gene regulatory elements. Carbonell and Miller [12], using a recombinant baculovirus with a mammalian expression cassette, detected reporter enzyme activity in a human lung carcinoma cell line. It was shown that AcMNPV could infect human hepatocytes and that the reporter gene luc (luciferase) was highly expressed from the cytomegalovirus (CMV) immediate early (IE) promoter [13]. The human hepatoblastoma cell line HepG2 and rat primary hepatocytes efficiently expressed a different reporter gene, lacZ, under the control of the Rous sarcoma virus (RSV) promoter inserted into AcMNPV [14]. By using a mammalian CAG promoter, derived from chicken ␤-actin promoter, baculovirus vector-delivered expression of several genes has been observed in human 
The baculovirus Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) expression system has been extensively used for expression of a wide variety of mammalian genes, including human ones. In addition to the very high-level expression in insect cells, the baculovirus-insect expression system provides a eukaryotic environment that is suitable for the proper post-translational modifications of the expressed proteins to take place. The expressed proteins are usually post-translationally modified such that they are almost identical to the native proteins [1] [2] [3] [4] [5] . AcMNPV enters cells of taxonomically diverse insects and can express genes under viral promoter control.
Baculoviruses, which are also used as biological pesticides [6] , traditionally infect the members of the Lepidopteran family. The infection in insect cells is characterized by production of two structurally and functionally distinct types of virions: the occluded or polyhedra-derived virion (PDV) and the budded virion (BV). The PDVs are responsible for primary infection and are embedded within the matrix of proteinaceous structures called occlusion bodies (OBs) or polyhedra. In a natural infection, the larvae ingest the OBs that contaminate and porcine cells as well as tumor cell lines from rat, porcine, and human sources [15, 16] (Table 1) . A recombinant baculovirus containing CMV-IE promoter, directly expressed green fluorescent protein (GFP), and the SV40 early promoter controlling neomycin phosphotransferase II have been shown to effectively deliver and express the transgenes in numerous cell types of human, primate, and rodent origin [17] . More recently, Sarkis et al. [18] showed that baculoviruses can be used for efficient gene delivery in the central nervous system. Baculoviruses have also been successfully used to deliver genes to rabbit carotid artery [19] and pancreatic islet cells [20] . Previously, Shoji et al. [15] constructed the recombinant baculoviruses AcCA39 and AcCA327 carrying hepatitis C virus (HCV) core and other structural genes, respectively, and the result indicated that HCV proteins were expressed and processed properly in different mammalian cell lines under the control of a CAG promoter. Subsequently, Delaney and Isom [21] reported a novel transient mechanism for studying hepatitis B virus (HBV) in the well-differentiated human HepG2 cell lines transduced by recombinant AcMNPV carrying the full-length HBV genome under the control of HBV promoter/enhancer with very high expression level. Very recently, the in vitro recombinant HBV-baculovirus system has been used to study antiviral drug sensitivity of wild-type and mutant HBV.
NOVELTY OF ACMNPV BASED VECTOR
The ability to efficiently transfer eukaryotic genes for reliable expression in different cell types has been central to the study of the gene of interest, leading to the development of several nonvirus-(physio-chemical) and virus-(retrovirus/adenovirus/adeno-associated virus) based techniques. The nonviral methods are, to varying degrees, deleterious to cells and require a large quantity of DNA and a comparatively low level of expression. The random integration of the retrovirus vectors, genomic rearrangements accompanying integration, immunogenic responses, and stochastic emergence of replicationcompetent adenoviruses and associated cytopathy remain significant drawbacks of gene transfer mediated by such virus-based vectors. Baculovirus has several striking features that make it an efficient tool as a mammalian cell-directed gene transfer vector. It has a double-stranded, circular DNA 80-200 kb in size. The rod-shaped nucleocapsid structure can accommodate an additional 100 kb or more of foreign DNA. The AcMNPV vectors are helper virus independent and therefore, relatively simpler and faster to construct. Transduction level approaches up to 100% with a very high expression level as compared with the other conventional physio-chemical and viral gene delivery systems. Moreover, it is noncytotoxic even at high multiplicity of infection (MOI).
FIG. 1.
Life cycle of baculoviruses. Upon ingestion, the OBs or polyhedra are lysed inside the gut of the larvae to release PDVs. Once the PDVs enter the nucleus through primary infection, the viral DNA is uncoated and undergoes replication and transcription, giving rise to BVs that in turn cause secondary infection. Also, the progeny viruses get embedded into OBs which are released upon death of the host.
MECHANISM OF ACMNPV ENTRY INTO MAMMALIAN CELLS
Uptake of baculoviruses by mammalian cells is considered to be a general phenomenon. The budded form of AcMNPV (Table 2) normally enters cells by endocytosis followed by low pH-facilitated fusion of the viral envelope (glycoprotein, gp64) with the endosomal membrane, thus allowing viral entry into the cytoplasm [22] . It has been shown that electrostatic interactions may be necessary for baculovirus binding to the mammalian cell surface. The data suggest that heparan sulfate moieties on the mammalian cell surface could be involved in binding of the virus [23] . It has been shown that phospholipids on the cell surface might serve as important docking points for baculoviral gp64, facilitating viral entry into mammalian cells [24] . In contrast, van Loo et al. [25] reported that such glycoprotein receptors are not necessary for efficient infection. They indicated a role for actin filaments in cytoplasmic transport of capsids preceded by virus entry by endocytosis and release of capsids into the cytoplasm upon an acid-induced fusion event. AcMNPV is internalized by mammalian cells of different origin [17] , including human and mouse hepatic cells [13] , with varying degrees of efficiency. The observed high efficiency and preferential gene transfer into hepatocytes is thought to be due to the presence of a particular receptor on the hepatic cell membrane. Inhibition of gene expression by blocking endosomal maturation suggests involvement of the endocytic pathway in the uptake route used by baculovirus in hepatocytes [13] . One insight into the mechanism of why certain cells are more efficiently transduced is suggested by Barsoum et al. [26] , who used a pseudotyped baculovirus with vesicular stomatitis virus G glycoprotein and compared its transduction efficiency into HeLa cells with unmodified virus. Their data suggest that inefficient gene expression in less susceptible cells is not due to a block in entry of the baculovirus into a cell, but rather, it is due to the inability of the virus to escape endosomes. However, the presence of a hepatocyte receptor in hepatic cells for binding of baculovirus cannot be ruled out.
INSERTION OF MAMMALIAN REGULATORY SIGNALS AND STABLE EXPRESSION OF FOREIGN GENES
The activity of the strong baculoviral promoter Ppolh, commonly used to transcribe transgene in insect cells, is silent in mammalian cells despite the presence, also in mammalian cells, of a host factor (polyhedrin promoter binding protein) which is required to nucleate the polyhedrin promoter-driven transcription machinery [27] . Therefore, the major prerequisite for constructing a recombinant AcMNPV for mammalian cell-directed gene transfer is the insertion of a strong mammalian gene regulatory element (Table 3) into the viral genome. However, HBV-expressing hepatocytes containing strong heterologous promoter elements from RSV and CMV, proximal to the HBV genome behaved differently in terms of HBV transcription and replication in vitro compared with natural infection in vivo [21] . This strongly suggests that endogenous regulatory elements are acting during delivery and expression of the gene of interest in native cells, specifically hepatic cells.
In addition to driving transient expression in mammalian cells, recombinant baculoviruses can also be used to generate stably transduced cell lines [15] . This occurs in a way that is similar to HBV infection in that, although the viral DNA does not integrate into the human genome as part of its life cycle, an integration event that enables the transduced hepatic cells to stably express some of the HBV genes occurs during persistent viral infection. Using a dominant selective marker in an expression cassette, they could obtain stable derivatives that maintained stable expression of a green fluorescent reporter protein (GFP) for multiple passages in culture. Analyses of cellular DNA revealed the presence of at least 12 kb of DNA derived from the viral input in Chinese hamster ovary (CHO) cells [17] . Another approach was used by Palombo et al. [28] , who used a chimeric baculovirus-AAV (adeno-associated virus) where the expression cassettes, controlled by mammalian promoters, were flanked by ITR (inverted terminal repeat) to exploit the ability of AAV to integrate into the genome of host cells. The ITR flanked cassettes integrated into a specific site on chromosome 19, which is characteristic of AAV integration.
ACMNPV AS A XENOVECTOR FOR GENE THERAPY
One of the most important target organs for gene therapy is the liver, where many inherited metabolic disorders The cutting edge in baculovirus gene therapy is the recent development of complement-resistant baculovirus [37] . In this novel approach, the human decay accelerating factor gene (DAF), which blocks the complement system at the central step of formation of both classical and alternative pathways by increasing rate of decay of C3bBb and C4b2a complex, is fused in-frame with baculoviral gp64 gene. DAF-gp64 is driven by the polyhedrin promoter, and the fusion protein is efficiently displayed on the surface of the complement-resistant baculovirus. The complement resistant baculoviruses allowed enhanced gene transfer in complement sufficient neonatal rats.
Another drawback to the use of baculoviruses as gene delivery vehicles is their production, purification, and concentration. The virus tends to aggregate upon centrifugation, the current method to concentrate the virus. However, this problem is likely to be solved by using a cationic exchange matrix to concentrate the baculoviruses [38] . Another important feature associated with this viral vector is that expression in mammalian cells appears to be regulated by epigenetic factors. Sarkis et al.
[18] have shown that inhibitors of histone deacetylases, such as butyrates, can markedly influence levels of expression. This could be important to regulate desired levels of expression.
ENGINEERING BACULOVIRUSES FOR IMPROVED FEATURES
Several strategies exist to engineer a baculovirus so that it can infect broad range of cell types. One of them is modifying the viral envelope to enhance the infectivity and tropism of the virus. For example, Barsoum et al. [26] showed that pseudotyping the baculoviral envelope with vesicular stomatitis G glycoprotein can enhance infectivity of engineered baculovirus towards the different cell lines tested. Pseudotyped viruses can be a very efficient tool for accurate target tissue-specific gene delivery. Pseudotyped baculovirus vectors with envelopes derived from neurotropic viruses, such as ␣-or rhabdoviruses, can be used to enhance transduction of nervous tissues. Similarly, pseudotyping with hepatotropic viruses, like Recently, Sollerbrant et al. [41] have shown that baculoviruses can be used as novel tools to produce largescale recombinant adenoviruses (rAAV), thereby circumventing present-day problems associated with rAAV production. Similarly, Cheshenko et al. [42] demonstrated that baculoviruses can also be used to generate fully deleted adenoviral vectors (FD-AdVs), which appear to be a promising tool for gene therapy. The contamination of vector preparation by helper viruses currently limits the use of FD-AdVs in gene therapy applications. Baculoviruses can also be used as possible cytotoxic vectors rather than therapeutic gene delivery vectors as demonstrated by Song and Boyce [43] , who efficiently killed human osteosarcoma cell lines with recombinant baculoviruses expressing p53. When combined with chemotherapy, greater than 95% of cells could be killed. With a suitable surface display moiety, recombinant baculovirus vectors expressing ribotoxins like restrictocin can be used to specifically destroy tumor cells.
RECOMBINANT ACMNPV AND BIOSAFETY
The AcMNPV propagates in insect cells but is inherently unable to replicate in mammalian cells, avoiding any risk of outbreak of the replication-competent virus. However, there is a possibility that regions of the AcMNPV-DNA could become integrated into the cellular genome in the culture. The persistence of large regions of the viral genome in cells raises the possibility that IE viral gene products could be expressed in the transduced mammalian cells. There is one report that one of these gene products, the IE-1, which is a translational transactivator, is involved in the activation of the early promoter he65 in both insect (TN-368) and mammalian (BHK-21) cell lines [44] . The observation that IE-1 activation of the he65 promoter depends on the presence of an inverted repeat of hr4left sequences suggests a comparable mechanism of IE-1 activation in insect and mammalian cells that might involve a direct interaction of IE-1 with the inverted repeat. However, the exact mechanism behind the regulation of this early viral promoter in mammalian cells is not known. It thus appears that much more work will be necessary to evaluate the safety of AcMNPV as a tool for human gene therapy. Although the virus does not appear to replicate in hepatocytes and the viral polyhedrin gene transcription unit remains inactive, further investigations will be required to determine whether any of the viral genes are expressed in mammalian cells [14] . Recent data suggest that baculovirus can enhance expression of inflammatory cytokines like TNF-␣, IL1-␣, and IL1-␤ in primary hepatocytes [45] . This is in line with the observation by Gronowski et al. [46] who showed that live baculovirus can induce interferons in addition to other cytokines through gp67. Moreover, like any recombinant organisms, recombinant AcMNPVs can be treated as if they were potential biohazards, and biosafety guidelines must be followed.
CONCLUSIONS AND FUTURE PROSPECTS
The above reports have illustrated the utility of recombinant baculoviruses as gene delivery vehicles for expression of foreign genes in mammalian cells, significantly expanding the range of such cell types as in vitro expression systems as well as for gene therapy. The broad range of susceptible cells, coupled with the relative ease of construction and propagation of the virus, makes the AcMNPV system a useful tool for studying expression and function of human and other mammalian gene products. Baculovirus vectors have thus emerged as novel and promising systems for gene delivery into mammalian cells of different origin, specifical- [47] [48] [49] [50] [51] , which are also present in mammalian cells, has added a new dimension to baculovirus-mediated gene therapy. It is of immense need to further evaluate the potential of AcMNPV-mediated gene delivery and expression of therapeutic proteins in native cells in vitro as well as in vivo. The identification of AcMNPV binding receptor on the cell membrane and elucidation of its structure would facilitate the understanding of virus-host interaction more precisely at the molecular level. This would enable alteration or modification of these molecules for enhanced uptake of the virus by a broad range of cells. Because AcMNPV is a doublestranded DNA virus, it would be very useful to clone therapeutic genes as well as cDNA of infectious RNA viruses towards antisense therapy approaches. However, the ability of heat-labile complement proteins to block AcMNPV infection of the mammalian cell or organ remains a challenge for the success of in vivo gene therapy, and it is necessary to identify these complement component-neutralizing agents and the consequences of post-neutralizing effects on the animal more elaborately. Also, the stable expression of the cloned genes in vivo is inevitable for therapeutic approaches, and further investigation will be required to determine exactly how much of the viral genome can be maintained and whether it is integrated into the host genome. Additionally, this system could facilitate an assessment of different promoters for their strength as well as temporal and spatial regulation across mammalian cells of different origin. The recent controversy surrounding gene therapy trials [52] has raised doubts about the safety of the animal virus-based vectors for gene therapy. The hitherto unexploited potential of baculoviruses as safe, efficient, and specific gene delivery vectors holds great promise for the development of a new generation of more efficient gene therapy vehicles in the future.
